[{"id":"cccc4a07-4111-4690-8a6c-b11f8091dbca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03082209","created_at":"2021-01-18T15:11:02.815Z","updated_at":"2024-07-02T16:35:59.314Z","phase":"Phase 1","brief_title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","source_id_and_acronym":"NCT03082209","lead_sponsor":"AbbVie","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 03/20/2017","start_date":" 03/20/2017","primary_txt":" Primary completion: 01/21/2022","primary_completion_date":" 01/21/2022","study_txt":" Completion: 01/21/2022","study_completion_date":" 01/21/2022","last_update_posted":"2022-12-09"},{"id":"5960154e-49bc-4681-a851-1b39b31a4731","acronym":"","url":"https://clinicaltrials.gov/study/NCT02983006","created_at":"2021-01-18T14:40:27.968Z","updated_at":"2025-02-25T14:36:58.593Z","phase":"Phase 1","brief_title":"Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma","source_id_and_acronym":"NCT02983006","lead_sponsor":"NYU Langone Health","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • DS-8273"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/23/2019","primary_completion_date":" 12/23/2019","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2021-10-18"},{"id":"76e96c90-172a-4d33-b0d4-aad64c0013c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01033240","created_at":"2021-04-09T02:52:34.130Z","updated_at":"2024-07-02T16:36:32.188Z","phase":"Phase 2","brief_title":"CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer","source_id_and_acronym":"NCT01033240","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • tigatuzumab (CS-1008)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 07/09/2010","start_date":" 07/09/2010","primary_txt":" Primary completion: 07/13/2012","primary_completion_date":" 07/13/2012","study_txt":" Completion: 09/09/2013","study_completion_date":" 09/09/2013","last_update_posted":"2021-04-08"},{"id":"ff3f2e67-cd18-4c1d-8576-19a17a15974f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02558140","created_at":"2023-10-21T07:12:17.830Z","updated_at":"2024-07-02T16:37:11.848Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02558140","lead_sponsor":"Hoffmann-La Roche","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 10/11/2015","start_date":" 10/11/2015","primary_txt":" Primary completion: 11/06/2017","primary_completion_date":" 11/06/2017","study_txt":" Completion: 11/06/2017","study_completion_date":" 11/06/2017","last_update_posted":"2018-04-04"},{"id":"1c573dd4-69f2-409c-b09f-5cc0b5a15d20","acronym":"","url":"https://clinicaltrials.gov/study/NCT01307891","created_at":"2021-01-18T05:19:25.464Z","updated_at":"2024-07-02T16:37:16.840Z","phase":"Phase 2","brief_title":"Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer","source_id_and_acronym":"NCT01307891","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • tigatuzumab (CS-1008)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2017-10-26"},{"id":"d4627bcf-9ab8-454b-a033-848eb947a528","acronym":"","url":"https://clinicaltrials.gov/study/NCT00517049","created_at":"2021-01-18T01:52:01.088Z","updated_at":"2024-07-02T16:37:21.391Z","phase":"Phase 2","brief_title":"A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)","source_id_and_acronym":"NCT00517049","lead_sponsor":"Genentech, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • drozitumab (RG7425)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 12/01/2009","study_completion_date":" 12/01/2009","last_update_posted":"2017-06-06"},{"id":"d4594130-d033-44b6-a56a-f74eead9a72a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03083743","created_at":"2021-01-18T15:11:28.965Z","updated_at":"2024-07-02T16:37:24.299Z","phase":"Phase 3","brief_title":"A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection","source_id_and_acronym":"NCT03083743","lead_sponsor":"Shanghai Gebaide Biotechnology Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dulanermin (AMG 951)"],"overall_status":"Unknown status","enrollment":" Enrollment 417","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2017-03-20"}]